2Q20 Wrap: Biotech bounce

COVID-19 vaccines drive biotech stocks up in 2Q20

INTRODUCTION

2Q20 Breaks Records

READ MORE

Generalists to stay?

READ MORE

All eyes on launches

READ MORE

2Q20 winners, losers

After the sudden, COVID-driven market declines that closed out 1Q20, biotech stocks rebounded in the second quarter with a force that has put shares up year to date. Many of the biggest moves came from companies developing vaccines or therapeutics for the new coronavirus, while others rode a market wave that floated biotech generally (see “Record Fund Flows”).

Companies starting 2Q20 with valuations above $10 billion added a median of 31.6% in market capitalization in the quarter, putting them up 26.2% YTD. Leading the pack

Read the full 845 word article

How to gain access

Continue reading with a
two-week free trial.